Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
about
Crizotinib: from discovery to accelerated development to front-line treatmentPersonalized Clinical Trials in Hepatocellular Carcinoma Based on Biomarker SelectionPersonalized treatment options for ALK-positive metastatic non-small-cell lung cancer: potential role for CeritinibTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment optionsMaintaining clarity: Review of maintenance therapy in non-small cell lung cancerSecond-Line Therapy for Advanced NSCLCMolecular pathology of non-small cell lung cancer: a practical guide.Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysisMechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized phase 3 study.Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung CancerPrior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma.Marked tumor response to crizotinib after 4 years of maintenance pemetrexed in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer.Clinical characteristics and outcomes of patients with primary lung adenocarcinoma harboring ALK rearrangements detected by FISH, IHC, and RT-PCR.Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA.Clinical benefit from pemetrexed before and after crizotinib exposure and from crizotinib before and after pemetrexed exposure in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancerA case series of lengthy progression-free survival with pemetrexed-containing therapy in metastatic non--small-cell lung cancer patients harboring ROS1 gene rearrangementsFDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.ALK in lung cancer: past, present, and future.Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitorsFluorescence in situ hybridization and immunohistochemistry as diagnostic methods for ALK positive non-small cell lung cancer patientsMolecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer.Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer care.Molecularly targeted therapies in non-small-cell lung cancer annual update 2014Epidermal growth factor receptor and K-Ras in non-small cell lung cancer-molecular pathways involved and targeted therapiesCrizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged non-small cell lung cancer and beyondMolecular Markers with Predictive and Prognostic Relevance in Lung CancerRelationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung CancerOncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer.Biomarkers that currently affect clinical practice: EGFR, ALK, MET, KRASTargeted therapies for lung cancer: clinical experience and novel agentsPredictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexedPROFILE 1014: lessons for the new era of lung cancer clinical research.Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncologyPemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancerA case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer.Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
P2860
Q26738385-414A0D60-520A-4F8A-9860-9A4EA2A3F968Q26738860-11210638-9C21-4F31-8995-3F245C32F62CQ26775817-129C8382-8D9A-423A-988A-AA2675B7F505Q26795555-59A796E1-15AA-4E91-A66B-E2CE1BF86553Q26820845-66E9E370-3E03-48C0-872B-D6CDCC4C899EQ26996389-1B8648B5-828E-4AB9-B34E-F269218BC52BQ27002398-B60D5353-C7D4-4FB7-8417-5F178DB16FE1Q27690919-F169A31D-1275-4244-B3A4-3AFBB28D2870Q27851671-6A3CAF0C-F333-48F9-BCD2-FB1439963F9FQ27851702-6285E3E7-8B23-41A1-9669-974B976F2F99Q27851956-8789041B-8A27-49EE-AADB-F1A8D796CCBBQ33407582-265B3451-FCE3-42E2-89BB-C8DFA44D1CA2Q33429242-15A3BA6B-49B7-4C3A-80C3-72447F26F547Q33706859-7018C496-83A4-40D8-9A60-4B8D393AABA0Q33733825-48F4BD0A-E8B4-486E-83F4-6DD5C1AA43D4Q33844713-2D465064-A374-4D9E-9F0A-129C2619FE71Q33898865-57C60092-8BCF-45C8-87E7-9148C7E900A5Q34019159-60240DE7-E249-4AD2-B63C-937A2CFA7747Q34145016-AF1000A8-091F-436B-943A-57A1FC04B799Q34359341-4C966E4D-DD10-4F78-AC58-846C1B6EDB05Q34402260-6562E341-169E-44DC-8C3B-DB017D5E82E0Q34564071-06B318F8-0E10-4962-946D-3B534ED8FBA2Q34566472-4D51688A-CA6A-4FF8-B7B3-93413F02717FQ34608584-F9FD91B1-1D55-4800-85EF-012A0B0A7ABDQ34814396-2B36E09E-AE15-4351-83B6-9344B937359EQ35136424-662A0CC9-93EF-49B8-820C-FDD5142111BCQ35549063-F0970AA7-6C02-44AE-8659-0F0F8469A2BFQ35596686-6CED5710-69E9-4EA1-AD5E-173309F9B848Q35763239-20C06303-3EE1-4587-B372-0F94CEAFE8D9Q35812568-6623B798-A5B1-46D3-A72F-F7A6B7E88CAEQ36016428-135286BD-6C6D-43BE-9249-CD7D8EB1D3EFQ36040606-5861BCC2-EF65-47A1-AE67-4CE689B9C2C9Q36054970-FC00B6C3-FFA3-447B-B461-A0FBE33307A8Q36070007-C6DBCD6A-FDEF-4BBB-AC59-277610736D7DQ36241808-B4EFE663-4F10-4BE5-AD34-A9C08EDC1FF1Q36405628-13B07B43-9AF9-42AD-B6D8-25340CDB51D9Q36474900-41E595A2-E29A-484F-9213-1B2E807D7B7AQ36554746-26C02483-BCB3-48C1-BA04-655C126655BEQ36729187-804596C9-BDA4-4D5C-9F72-13D1111C3AADQ37041209-EFCFB00E-8EF9-49BC-8876-9952455E9D55
P2860
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Anaplastic lymphoma kinase gen ...... n-free survival on pemetrexed.
@ast
Anaplastic lymphoma kinase gen ...... n-free survival on pemetrexed.
@en
type
label
Anaplastic lymphoma kinase gen ...... n-free survival on pemetrexed.
@ast
Anaplastic lymphoma kinase gen ...... n-free survival on pemetrexed.
@en
prefLabel
Anaplastic lymphoma kinase gen ...... n-free survival on pemetrexed.
@ast
Anaplastic lymphoma kinase gen ...... n-free survival on pemetrexed.
@en
P2093
P2860
P1476
Anaplastic lymphoma kinase gen ...... n-free survival on pemetrexed.
@en
P2093
Ana B Oton
Angela M Davies
Anna E Barón
D Ross Camidge
Marileila Varella-Garcia
Robert C Doebele
Scott A Kono
Sonia Okuyama
Wilbur Franklin
P2860
P304
P356
10.1097/JTO.0B013E31820CF053
P577
2011-04-01T00:00:00Z